Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, 60616, USA.
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Eye (Lond). 2020 Aug;34(8):1371-1379. doi: 10.1038/s41433-020-0809-0. Epub 2020 Feb 18.
Recent advances in pharmacological agents have led to successful treatment of a variety of retinal diseases such as neovascular age-related macular degeneration (AMD), diabetic macular oedema (DMO), and retinal vascular occlusions (RVO). These treatments often require repeated drug injections for an extended period of time. To reduce these repeated treatment burdens, minimally invasive drug delivery systems are needed. An ideal therapy should maintain effective levels of drug for the intended duration of treatment following a single application, recognising that a significant number of months of therapy may be required. There are numerous approaches under investigation to improve treatment options. This review will highlight the advantages and limitations of selected drug delivery systems of novel biomaterial implants and depots. The main emphasis will be placed on less invasive, longer acting, sustained release formulations for the treatment of retinal disorders.
近年来，药理学制剂的进步使得多种视网膜疾病（如新生血管性年龄相关性黄斑变性（AMD）、糖尿病性黄斑水肿（DMO）和视网膜血管阻塞（RVO））的治疗取得了成功。这些治疗通常需要长时间内重复进行药物注射。为了减轻这些重复治疗的负担，需要开发微创药物递送系统。一种理想的疗法应该在单次应用后维持有效的药物水平，以达到预期的治疗持续时间，因为可能需要几个月的治疗时间。目前有许多研究方法旨在改善治疗选择。本综述将重点介绍新型生物材料植入物和储存库的选定药物递送系统的优缺点。主要强调用于治疗视网膜疾病的微创、长效、持续释放制剂。
